A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

计划入组 910 人 · 首次发布于 2026 年 7 月 29 日

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

计划入组 675 人 · 首次发布于 2024 年 8 月 16 日

ALFA-SLE (ALFA-SLE)

计划入组 48 人

Tabirafusp tedromer

Pabinafusp alfa

bifikafusp alfa + onfekafusp alfa

Alfa Wassermann SpA

Italy

Hospital General Puyo

Ecuador

Protalix Biotherapeutics

Israel

Kodiak Sciences to Report DAYBREAK Phase 3 Topline Data for Zenkuda and KSI-501 in Wet AMD

Kodiak's Zenkuda and tabirafusp-ted hit primary endpoints in pivotal DAYBREAK trial in wet AMD

Kodiak Sciences' Tarcocimab Tedromer Shows Promise in Diabetic Retinopathy Treatment